ABUS vs. ALT, KALV, KMDA, FSTX, MGTA, MOR, RNA, TGTX, ACAD, and GPCR
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Altimmune (ALT), KalVista Pharmaceuticals (KALV), Kamada (KMDA), F-star Therapeutics (FSTX), Magenta Therapeutics (MGTA), MorphoSys (MOR), Avidity Biosciences (RNA), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), and Structure Therapeutics (GPCR). These companies are all part of the "medical" sector.
Arbutus Biopharma (NASDAQ:ABUS) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
In the previous week, Altimmune had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 18 mentions for Altimmune and 13 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.28 beat Altimmune's score of 0.07 indicating that Arbutus Biopharma is being referred to more favorably in the media.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Arbutus Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
Arbutus Biopharma has a net margin of -572.81% compared to Altimmune's net margin of -22,645.37%. Altimmune's return on equity of -46.96% beat Arbutus Biopharma's return on equity.
Arbutus Biopharma has higher revenue and earnings than Altimmune. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma currently has a consensus price target of $4.33, suggesting a potential upside of 35.42%. Altimmune has a consensus price target of $17.25, suggesting a potential upside of 167.23%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Arbutus Biopharma.
Arbutus Biopharma received 378 more outperform votes than Altimmune when rated by MarketBeat users. Likewise, 70.93% of users gave Arbutus Biopharma an outperform vote while only 70.00% of users gave Altimmune an outperform vote.
Summary
Arbutus Biopharma beats Altimmune on 9 of the 17 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
